Evolent Health, Inc (EVH) Rating Reiterated by Cowen and Company

Evolent Health, Inc (NYSE:EVH)‘s stock had its “outperform” rating reaffirmed by stock analysts at Cowen and Company in a research report issued to clients and investors on Friday. They currently have a $29.00 target price on the technology company’s stock, down from their previous target price of $33.00. Cowen and Company’s price objective would indicate a potential upside of 59.78% from the company’s previous close.

Several other brokerages also recently issued reports on EVH. BidaskClub downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. Jefferies Group LLC restated a “buy” rating and set a $28.00 price objective on shares of Evolent Health in a research report on Wednesday, September 6th. ValuEngine downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. J P Morgan Chase & Co restated a “buy” rating on shares of Evolent Health in a research report on Friday, August 18th. Finally, Leerink Swann set a $32.00 price objective on shares of Evolent Health and gave the stock a “buy” rating in a research report on Friday, August 18th. Three equities research analysts have rated the stock with a sell rating, twelve have given a buy rating and one has given a strong buy rating to the company. Evolent Health has a consensus rating of “Buy” and an average target price of $28.45.

Evolent Health (NYSE:EVH) opened at 18.15 on Friday. The firm’s market cap is $1.19 billion. Evolent Health has a 12-month low of $14.50 and a 12-month high of $25.66. The firm has a 50-day moving average price of $17.43 and a 200 day moving average price of $17.43.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Monday, August 7th. The technology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $107.30 million during the quarter, compared to the consensus estimate of $104.45 million. Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. The business’s revenue for the quarter was up 89.9% compared to the same quarter last year. During the same period last year, the business posted ($0.20) earnings per share. Equities research analysts forecast that Evolent Health will post ($0.41) EPS for the current year.

WARNING: “Evolent Health, Inc (EVH) Rating Reiterated by Cowen and Company” was posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://transcriptdaily.com/2017/10/08/evolent-health-inc-evh-rating-reiterated-by-cowen-and-company.html.

In other news, COO Thomas Peterson III sold 40,540 shares of Evolent Health stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $26.00, for a total value of $1,054,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Frank J. Williams sold 16,300 shares of Evolent Health stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $23.73, for a total transaction of $386,799.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,507 shares of company stock valued at $1,631,054. 8.79% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd acquired a new position in Evolent Health during the second quarter valued at approximately $635,000. Castleark Management LLC acquired a new position in Evolent Health during the second quarter valued at approximately $14,299,000. California State Teachers Retirement System raised its position in Evolent Health by 116.8% during the second quarter. California State Teachers Retirement System now owns 68,315 shares of the technology company’s stock valued at $1,732,000 after purchasing an additional 36,800 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Evolent Health by 123.6% during the second quarter. The Manufacturers Life Insurance Company now owns 30,005 shares of the technology company’s stock valued at $760,000 after purchasing an additional 16,587 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its position in Evolent Health by 492.2% during the second quarter. Cubist Systematic Strategies LLC now owns 82,874 shares of the technology company’s stock valued at $2,101,000 after purchasing an additional 68,880 shares in the last quarter. Institutional investors and hedge funds own 82.51% of the company’s stock.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply